



Substitute for form 1449A/PTO				Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/685,224		
				Filing Date	October 14, 2003		
				First Name Inventor	Ding, et al.		
(Use several sheets if necessary)							
Sheet	1	of	1	Attorney Docket Number	20861 US3		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code <sup>2</sup> (if known)				
	A						
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>4</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)			
AW	B1		WO99/21845		Agouron Pharmaceuticals Inc.	05/06/1999	
	B2		WO00/75120		Agouron Pharmaceuticals Inc.	12/14/2000	
	B3		WO97/16447		Mitotix Inc.	05/09/1997	
	B4		WO99/43675		Hoechst Marion Roussel Inc.	09/02/1999	
	B5		WO99/43676		Hoechst Marion Roussel Inc.	09/02/1999	
	B6		WO98/33798		Warner Lambert Co.	08/06/1998	
	B7		WO99/09030		Warner Lambert Co.	02/25/1999	
	B8		WO00/39101		Astrazeneca Ltd.	07/06/2000	
	B9		WO00/12485		Zeneca Ltd.	03/09/2000	
	B10		WO99/24416		Bristol-Myers Squibb Co.	03/09/1999	
	B11		WO99/21845		Agouron Pharmaceuticals Inc.	05/06/1999	
	B12		WO 00/26202		Pharmacia & Upjohn S.P.A.	05/11/2000	
	B13		WO 01/56567		Novo Nordisk A/S	08/09/2001	
	B14		WO 01/60816		Amgen Inc.	08/23/2001	
	B15		WO 01/79198		Agouron Pharmaceuticals, Inc.	12/25/2001	
AW	B16		WO 02/12250		Agouron Pharmaceuticals, Inc.	02/14/2002	
<b>NON PATENT LITERATURE DOCUMENTS</b>							
AW	C1	Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vol. 92 pgs. 376-387					
	C2	Chong, Wesley, K. M., Presentation at Gordon Conference on Medicinal Chemistry, Colby Sawyer College, New London, NH "Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August 2, 1999 (Copy of Conference Handout Enclosed)					
	C3	Fischer et al., Expert Opin. Investig. Drugs 12(6) pgs. 955-970 (2003)					
AW	C4	Grant et al., Drug Resistance Vol. 6, pgs. 15-26 (2003)					
Examiner Signature	Date Considered 12/01/05						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

137760